As is known, in early and locally advanced BC, especially in triple-negative and HER2-positive variants, the achievement of a pathological complete response (pCR) has important prognostic value and is associated with an increase in OS and PFS [162,163,164,165,166,167,168,169]. This evidence concerns the gene ERBB2 and breast cancer.